Back to News
Market Impact: 0.25
Oncology Institute Q3 Earnings Call Highlights
Source: marketbeat.com
Corporate EarningsCompany Fundamentals
Oncology Institute (NASDAQ: STLN), which executives referred to as Starling Oncology, reported a second consecutive quarter of positive adjusted EBITDA in Q3. Specialty pharmacy growth and stronger drug margins boosted results; the article provides no figures for the improvement.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
STLN0.55
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FTSE 100 today: Stocks slump as global tech rout deepens